EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ADAMTS-13 R1206K variant exhibits an open conformation and an enhanced proteolytic activity toward von Willebrand factor

Szumam Liu, Xiaxin Dong, Quintijn Bonnez, Zhirong Chai, Chan Meng, Madison Gil, Karen Vanhoorelbeke, Konstantine Halkidis, X Long Zheng

Journal of Thrombosis and Haemostasis · 2026-07 · 24 (7) · 2436-2448

DOI: 10.1016/j.jtha.2026.03.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-07. Verfasst von Szumam Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA; Institute of Reproductive and Dev…. Hauptthemen laut MEDLINE: ADAMTS13 Protein, von Willebrand Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Hemostasis and Thrombosis Research Society, American Heart Association Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy caused by severe deficiency of ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, 13), a plasma metalloprotease that cleaves von Willebrand factor (VWF). Recombinant ADAMTS-13 has been developed for treatment of TTP, but it requires a high dose and frequent administrations to achieve therapeutic efficacy. OBJECTIVES: The present study aims to identify more efficacious ADAMTS-13 variants for potential management of TTP. METHODS: Site-directed mutagenesis, recombinant protein production and purification, enzyme kinetic and binding assays, and microfluidic thrombus formation were all used in the study. RESULTS: ADAMTS-13 R1206K variant exhibits a significantly increased activity compared with wild-type ADAMTS-13 for proteolytic cleavage of multimeric VWF and its surrogate peptide. Additionally, the R1206K is significantly more efficacious for inhibiting platelet adhesion and aggregation on a collagen-coated surface under arterial flow. Biolayer interferometry assay reveals a faster association kinetics (ka) between R1206K and VWF73L1603A substrate but a reduced binding affinity between R1206K and autoantibodies against ADAMTS-13, derived from immune-mediated TTP. Consistent with these results, the fluorescent energy transfers (FRETS)-VWF73 assay reveals a higher IC50 for autoantibodies (IgG4 4-16 and 4-20) to inhibit the R1206K than wild-type ADAMTS-13. CONCLUSION: These results demonstrate that ADAMTS-13 R1206K variant has an enhanced enzymatic activity, resulting from the disruption of autoinhibition that leads to an open conformation, which increases its substrate binding but reduces its autoantibody inhibition. This gain-of-function ADAMTS-13 variant may be further explored for the management of TTP and perhaps other inflammatory thrombotic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 Proteinvon Willebrand FactorHumansProteolysisPurpura, Thrombotic ThrombocytopenicProtein ConformationKineticsProtein BindingMutagenesis, Site-DirectedPlatelet AdhesivenessAutoantibodiesPlatelet AggregationRecombinant ProteinsStructure-Activity Relationship

Stichwörter der Autor:innen

ADAMTS13arginine methylationthrombosisthrombotic thrombocytopenic purpuratreatmentvon Willebrand factor

Substanzen

ADAMTS13 Proteinvon Willebrand FactorADAMTS13 protein, humanAutoantibodiesRecombinant Proteins

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA; Institute of Reproductive and Developmental Sciences, The University of Kansas Medical Center, Kansas C…
  • Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Laboratory for Thrombosis Research, Kortrijk, Belgium.
  • Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Institute of Reproductive and Developmental Sciences, The University of Kansas Medical Center, Kansas City, Kansas, USA; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.

Förderung

  • NHLBI NIH HHS
  • Hemostasis and Thrombosis Research Society
  • American Heart Association Inc
  • National Heart Lung and Blood Institute

Zitieren

APA

Liu, S., Dong, X., Bonnez, Q., Chai, Z., Meng, C., Gil, M., Vanhoorelbeke, K., Halkidis, K., & Zheng, X. L. (2026). ADAMTS-13 R1206K variant exhibits an open conformation and an enhanced proteolytic activity toward von Willebrand factor. Journal of Thrombosis and Haemostasis, 24(7), 2436-2448. https://doi.org/10.1016/j.jtha.2026.03.010

Vancouver

Liu S, Dong X, Bonnez Q, Chai Z, Meng C, Gil M, et al. ADAMTS-13 R1206K variant exhibits an open conformation and an enhanced proteolytic activity toward von Willebrand factor. Journal of Thrombosis and Haemostasis. 2026;24(7):2436-2448. doi:10.1016/j.jtha.2026.03.010

BibTeX
@article{Liu2026,
  author = {Liu, Szumam and Dong, Xiaxin and Bonnez, Quintijn and Chai, Zhirong and Meng, Chan and Gil, Madison and Vanhoorelbeke, Karen and Halkidis, Konstantine and Zheng, X Long},
  title = {ADAMTS-13 R1206K variant exhibits an open conformation and an enhanced proteolytic activity toward von Willebrand factor},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {7},
  pages = {2436--2448},
  doi = {10.1016/j.jtha.2026.03.010}
}
Kostenlos starten →